Reactions Weekly

, Volume 1673, Issue 1, pp 146–146 | Cite as

Dabrafenib/trametinib/vemurafenib

Acquired resistance during treatment of melanoma: 2 case reports
Case report
  • 15 Downloads

Reference

  1. Kulkarni A, et al. BRAF fusion as a novel mechanism of acquired resistance to vemurafenib in BRAFV600E mutant melanoma. Clinical cancer research: an official journal of the American Association for Cancer Research 23: 5631-5638, No. 18, Sep 2017. Available from: URL: http://doi.org/10.1158/1078-0432.CCR-16-0758 - USA

Copyright information

© Springer International Publishing AG 2017

Personalised recommendations